A Randomized Controlled Trial: Colistin Alone or Colistin and Meropenem: Which Is More Effective for the Management of Urinary Tract Infections? Colistin with and without Meropenem for Management of Urinary Tract Infections
Novelty in Biomedicine,
Vol. 10 No. 4 (2022),
2 December 2022
,
Page 213-218
https://doi.org/10.22037/nbm.v10i4.38197
Abstract
Background: Colistin is a common antibiotic used to treat urinary tract infections (UTIs) caused by gramnegative bacteria. In recent years, due to the increasing resistance, consumption of colistin alone could lead to
treatment failures. This study aimed to compare the effectiveness of colistin alone with colistin and meropenem
to treat patients with urinary tract infections.
Materials and Methods: In this randomized, open-label, parallel groups controlled trial, hospitalized patients
with urinary tract infections were included. Patients were randomly allocated to the control group (n=35) that
received colistin (1 mIU every 12 hours) and the intervention group (n=35) that received colistin (1 mIU every
12 hours) with meropenem (1gr every 8 hours). An infectious disease specialist evaluated the therapeutic
responses 48-72 hours after admission. Cessation of fever, improvement of symptoms and signs, and negative
urine culture within 48 hours were considered successful therapeutic responses.
Results: The mean length of hospitalization was longer in the control group (4.74±0.78 days) compared with
the intervention group (4.26±0.56 days) (P=0.004). The prevalence of fever cessation had no significant
difference between the two groups at any time (P>0.05). Also, there was no significant difference between
the two groups at any time, considering vital signs, irritative urinary symptoms, nausea and vomiting, and
flank pain (P>0.05).
Conclusion: The administration of colistin and meropenem to treat UTIs was associated with a shorter
length of hospital stay. However, regarding response to treatment, it did not matter if they were treated with
colistin alone or with combination therapy (colistin and meropenem)
- Colistin, Drug resistance, Gram-negative bacteria, Meropenem, Urinary Tract Infections
How to Cite
References
Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. Therapeutic advances in urology. 2019;11:1756287219832172.
Chu CM, Lowder JL. Diagnosis and treatment of urinary tract infections across age groups. American journal of obstetrics and gynecology. 2018;219(1):40-51.
Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nature reviews microbiology. 2015;13(5):269-84.
Kim JW, Lee YJ, Chung JW, Ha YS, Lee JN, Yoo ES, et al. Clinical characteristics of postoperative febrile urinary tract infections after ureteroscopic lithotripsy. Investigative and clinical urology. 2018;59(5):335-41.
Tan CW, Chlebicki MP. Urinary tract infections in adults. Singapore medical journal. 2016;57(9):485.
Colgan R, Keating K, Dougouih M. Survey of symptom burden in women with uncomplicated urinary tract infections. Clinical drug investigation. 2004 Jan;24(1):55-60.
Gajdács M, Ábrók M, Lázár A, Burián K. Increasing relevance of Gram-positive cocci in urinary tract infections: A 10-year analysis of their prevalence and resistance trends. Scientific Reports. 2020;10(1):1-1.
Behzadi P. Classical chaperone-usher (CU) adhesive fimbriome: uropathogenic Escherichia coli (UPEC) and urinary tract infections (UTIs). Folia microbiologica. 2020;65(1):45-65.
Yelin I, Snitser O, Novich G, Katz R, Tal O, Parizade M, Chodick G, Koren G, Shalev V, Kishony R. Personal clinical history predicts antibiotic resistance of urinary tract infections. Nature medicine. 2019;25(7):1143-52.
Sorlí L, Luque S, Li J, Campillo N, Danés M, Montero M, et al. Colistin for the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: Dose is critical. Journal of Infection. 2019;79(3):253-61.
CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fifth Informational Supplement. Clinical and Laboratory Standards Institute; Wayne, PA, USA: 2015. CLSI document M100-S25.
Voicu MN, Ahmet AM, Turcu-Stiolica M, Turcu-Stiolica A, Barbulescu AL, Popescu F. Antibiotic Resistance, Still a Global Challenge. Current Health Sciences Journal. 2021;47(2):284-9.
Montero M, Horcajada JP, Sorli L, Alvarez-Lerma F, Grau S, Riu M, et al. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection. 2009;37(5):461-5.
Karakkattu J, Mohan A, James E, Kumar A. Effectiveness and safety of colistin in multi drug resistant urinary tract infections. J Appl Pharm Sci. 2017;7(9):148-52.
Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. The Lancet Infectious Diseases. 2018;18(4):391-400.
Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) Gram-negative bacteria. BMC infectious diseases. 2005;5(1):1-7.
Falagas ME, Rafailidis PI, Kasiakou SK, Hatzopoulou P, Michalopoulos A. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin–meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clinical microbiology and infection. 2006;12(12):1227-30.
Katip W, Uitrakul S, Oberdorfer P. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii. International Journal of Infectious Diseases. 2020;97:391-5.
Abdul-Mutakabbir JC, Yim J, Nguyen L, Maassen PT, Stamper K, Shiekh Z, et al. In vitro synergy of colistin in combination with meropenem or tigecycline against carbapenem-resistant Acinetobacter baumannii. Antibiotics. 2021;10(7):880.
Cuba GT, Ramos JF, Kiffer CR. Re:‘Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes’ by Nutman et al. Clinical Microbiology and Infection. 2021;27(3):497-8.
- Abstract Viewed: 181 times
- pdf Downloaded: 164 times